1. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). (March 2016) Authors: Lim, Sun Min; Cho, Byoung Chul; Kim, Sang-We; Kang, Seok Yun; Heo, Dae Seog; Kim, Heung Tae; Lee, Dae Ho; Kim, Dong-Wan; Jung, Minkyu; Choi, Jin-Hyuk; Shim, Hyo Sup; Choi, Jong Rak; Kim, Joo-Hang Journal: Lung cancer Issue: Volume 93(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). (March 2016) Authors: Lim, Sun Min; Cho, Byoung Chul; Kim, Sang-We; Kang, Seok Yun; Heo, Dae Seog; Kim, Heung Tae; Lee, Dae Ho; Kim, Dong-Wan; Jung, Minkyu; Choi, Jin-Hyuk; Shim, Hyo Sup; Choi, Jong Rak; Kim, Joo-Hang Journal: Lung cancer Issue: Volume 93(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. (May 2018) Authors: Choi, Moon Ki; Ahn, Jin Seok; Kim, Young-Chul; Cho, Byoung Chul; Oh, In-Jae; Kim, Sang-We; Lee, Jong Seok; Kim, Joo-Hang; Ahn, Myung-Ju; Park, Keunchil Journal: Lung cancer Issue: Volume 119(2018) Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Issue 12 (August 2015) Authors: Lim, Sun Min; Chung, Woong Youn; Nam, Kee-Hyun; Kang, Sang-Wook; Lim, Jae Yun; Kim, Hoon-Gu; Shin, Seong Hoon; Sun, Jong-Mu; Kim, Seong-Geun; Kim, Joo-Hang; Kang, Chan Woo; Kim, Hye Ryun; Cho, Byoung Chul Journal: European journal of cancer Issue: Volume 51:Issue 12(2015:Aug.) Page Start: 1588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. Issue 1 (December 2016) Authors: Cho, Arthur; Hur, Jin; Moon, Yong; Hong, Sae; Suh, Young; Kim, Yun; Im, Dong; Hong, Yoo; Lee, Hye-Jeong; Kim, Young; Shim, Hyo; Lee, Jae; Kim, Joo-Hang; Choi, Byoung Journal: BMC cancer Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Issue 4 (April 2018) Authors: Garassino, Marina Chiara; Cho, Byoung-Chul; Kim, Joo-Hang; Mazières, Julien; Vansteenkiste, Johan; Lena, Hervé; Corral Jaime, Jesus; Gray, Jhanelle E; Powderly, John; Chouaid, Christos; Bidoli, Paolo; Wheatley-Price, Paul; Park, Keunchil; Soo, Ross A; Huang, Yifan; Wadsworth, Catherine; Dennis, P... Journal: Lancet oncology Issue: Volume 19:Issue 4(2018) Page Start: 521 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021) Authors: Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Issue 2 (February 2015) Authors: Baek, Jin Ho; Sun, Jong-Mu; Min, Young Joo; Cho, Eun Kyung; Cho, Byoung Chul; Kim, Joo-Hang; Ahn, Myung-Ju; Park, Keunchil Journal: Lung cancer Issue: Volume 87:Issue 2(2015:Feb.) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Issue 2 (February 2015) Authors: Baek, Jin Ho; Sun, Jong-Mu; Min, Young Joo; Cho, Eun Kyung; Cho, Byoung Chul; Kim, Joo-Hang; Ahn, Myung-Ju; Park, Keunchil Journal: Lung cancer Issue: Volume 87:Issue 2(2015:Feb.) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗